You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice

 

Online download statistics by month:

Online download statistics by month: December 2020 to March 2024

AbstractFullPdf
Dec 202014814939
Jan 202116616798
Feb 2021575724
Mar 2021666635
Apr 202131531524
May 2021626221
Jun 2021969623
Jul 2021585843
Aug 202110010030
Sep 2021565633
Oct 2021888851
Nov 2021636347
Dec 2021414122
Jan 2022444518
Feb 2022424218
Mar 2022454518
Apr 2022525937
May 2022515525
Jun 2022636623
Jul 2022556529
Aug 2022586015
Sep 2022414341
Oct 2022444832
Nov 2022424213
Dec 2022272711
Jan 2023353612
Feb 2023505230
Mar 2023313630
Apr 2023282922
May 2023464621
Jun 2023454524
Jul 2023292910
Aug 2023464611
Sep 2023727216
Oct 2023646412
Nov 2023434315
Dec 2023545624
Jan 2024384114
Feb 2024737416
Mar 2024424325
Total257626271052